Related Experiment Video
Updated: Apr 18, 2026
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
Multi-Epitope mRNA Vaccine Targeting Dabie Bandavirus Glycoprotein: An Immunoinformatics-Based Study
Sk Faisal Ahmed1, Md Shah Paran1,2, Md Masudur Rahman Munna1
1DawniLab, Dawn of Bioinformatics Ltd., Dhaka, Bangladesh.
Abstract:
Dabie bandavirus (DBV), also called severe fever with thrombocytopenia syndrome virus (SFTSV), is a tick-borne virus that leads to a serious illness with high fever, low platelets, bleeding risks, and organ damage. Death rates can reach 5% to 30% in affected areas like China, South Korea, and Japan, where cases continue to rise. No approved vaccines or specific treatments are available, prompting the World Health Organization to mark it as a priority emerging infectious disease. This in silico study designs a multi-epitope mRNA vaccine candidate targeting the virus's membrane glycoprotein. After reviewing 1042 virus sequences, 9 cytotoxic T-cell (cytotoxic T lymphocyte [CTL]), 6 helper T-cell (helper T lymphocyte [HTL]), and 5 B-cell epitopes were chosen for their high conservation, predicted antigenicity, safety (non-toxic, low allergenicity), and lack of similarity to human proteins, achieving 94.77% global population coverage. The construct included beta-defensin-3 as an adjuvant. Computational predictions indicated favorable features: structural stability, potential binding to immune receptors (Toll-like receptor 3 [TLR3] and Toll-like receptor 4 [TLR4]), consistent behavior in molecular dynamics simulations (100 ns), encouraging patterns in immune response modeling, and good codon optimization for possible expression. These results are hypothesis-generating and based solely on in silico tools and require experimental validation, including in vitro studies, immunogenicity tests, and animal challenge models to assess any real-world potential.
Insights
A novel mRNA vaccine candidate was computationally designed to combat severe fever with thrombocytopenia syndrome virus (SFTSV), a dangerous tick-borne illness. This vaccine targets key viral epitopes, showing promise for broad population coverage and potential immune response.
Area of Science:
- Virology and Immunology
- Vaccine Design
- Computational Biology
Background:
- Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tick-borne pathogen causing severe illness with high mortality rates.
- Current lack of approved vaccines or treatments for SFTSV highlights its status as a priority emerging infectious disease.
- SFTSV is prevalent in East Asia, with rising case numbers in China, South Korea, and Japan.
Purpose of the Study:
- To design a multi-epitope mRNA vaccine candidate against the SFTSV membrane glycoprotein using in silico methods.
- To identify and select conserved, safe, and immunogenic epitopes for vaccine development.
- To computationally evaluate the vaccine candidate's stability, immune receptor binding, and potential efficacy.
Main Methods:
- Analysis of 1042 SFTSV sequences to identify conserved epitopes.
- Selection of cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and B-cell epitopes based on antigenicity, safety, and human protein similarity.
- In silico design of an mRNA vaccine construct incorporating beta-defensin-3 as an adjuvant, followed by computational prediction of its properties.
Main Results:
- A vaccine construct was designed, incorporating 9 CTL, 6 HTL, and 5 B-cell epitopes, achieving 94.77% global population coverage.
- Computational analyses predicted favorable vaccine characteristics, including structural stability, potential binding to TLR3 and TLR4, and promising immune response modeling.
- Molecular dynamics simulations (100 ns) indicated stable behavior, and codon optimization suggested potential for expression.
Conclusions:
- The in silico study presents a promising multi-epitope mRNA vaccine candidate against SFTSV.
- The designed vaccine exhibits favorable predicted properties for stability, immunogenicity, and broad population coverage.
- Experimental validation is crucial to confirm these computational findings and assess the vaccine's real-world potential.
